HRSA Greenlights Nine Drugs for New Pilot Program to Test 340B Rebate Model
- October 31, 2025
The Health Resources and services Administration (HRSA) approved nine drugs from eight pharmaceutical manufacturers including Bristol Myers Squibb Co., AstraZeneca PLC, and Merck & Co. to participate in a new pilot program that will test a rebate model for providing discounts under the 340B drug pricing program.
ARTICLE TAGS
You must be logged in to access this content.